Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 27, 2023

Primary Completion Date

February 28, 2024

Study Completion Date

February 28, 2024

Conditions
Parkinson Disease
Interventions
DRUG

Apomorphine Cartridge

Staccato Cartridge

Trial Locations (13)

28265

Accellacare of Piedmont Healthcare, Statesville

30030

CenExel iResearch Atlanta (Decatur), Decatur

33133

Visionary Investigators Network, Miami

33308

Holy Cross Health, Fort Lauderdale

33980

Parkinson's Disease Treatment Center of Southwest Florida, Port Charlotte

34205

Bradenton Research Center, Inc., Bradenton

37067

KCA Neurology, (Part of Ki Health Partners, LLC), Franklin

48334

Quest Research Institute, Farmington Hills

75035

Lone Star Neurology, (Part of Ki Health Partners, LLC), Frisco

80113

Cenexel Rocky Mountain Clinical Research, Englewood

85258

Movement Disorders Center of Arizona, Scottsdale

85710

Tuscon Neuroscience Research (M3 Wake Research), Tucson

92708

The Parkinson's and Movement Disorder Institute, Fountain Valley

All Listed Sponsors
collaborator

Peachtree BioResearch Solutions Inc.

UNKNOWN

collaborator

DSG, Inc

UNKNOWN

collaborator

ISS, Inc.

INDUSTRY

lead

Alexza Pharmaceuticals, Inc.

INDUSTRY